Ignite Creation Date:
2025-12-26 @ 11:12 AM
Ignite Modification Date:
2025-12-26 @ 11:12 AM
Study NCT ID:
NCT00436228
Status:
COMPLETED
Last Update Posted:
2008-10-13
First Post:
2007-02-15
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
To Study And Compare Bioavailability And Safety Of Four Different Formulations Of The Study Drug
Sponsor:
GlaxoSmithKline
Organization:
Study Overview
Official Title:
An Open-Label, Randomized, Crossover Study to Estimate the Formulation Effect on the Relative Bioavailability of Single Dose Oral SB-742510 in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
SB-742510 is a semi-synthetic pleuromutilin antibiotic that is being developed for treatment of respiratory infections.
The purpose of this study is to estimate the bioavailability of four different formulations and to evaluate the safety of each of the four formulations
The purpose of this study is to estimate the bioavailability of four different formulations and to evaluate the safety of each of the four formulations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: